Nicholas J. Slipek

This paper develops a base editing platform to efficiently and safely engineer CAR T cells with multiple gene knockouts and insertions.

This paper uses base editing to introduce dominant-negative mutations in FAS and TGFβR2 in primary T cells, enhancing their anti-tumor efficacy and persistence in solid tumor models.

This study enhances CAR-NK cell functionality using non-viral base editing and transposon integration, showing improved therapeutic potential in Burkitt's lymphoma models.

This study shows that deleting CISH enhances T cell anti-cancer functions more than other intracellular checkpoints, improving tumor antigen recognition and killing in CAR-T cells.

This study demonstrates that genetically engineered memory T cells can deliver enzyme replacement therapy for mucopolysaccharidosis type I, reducing GAG levels in multiple tissues for up to 22 weeks.

This study develops a method to efficiently edit multiple genes in human T cells using base editors, reducing off-target effects and improving safety for immunotherapy.